- Home
- PLRX vs CNTX Comparison
PLRX vs CNTX Comparison
Compare PLRX & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- CNTX
- Stock Information
- Founded
- PLRX 2015
- CNTX 2015
- Country
- PLRX United States
- CNTX United States
- Employees
- PLRX N/A
- CNTX N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- PLRX Health Care
- CNTX Health Care
- Exchange
- PLRX Nasdaq
- CNTX Nasdaq
- Market Cap
- PLRX 84.7M
- CNTX 78.0M
- IPO Year
- PLRX 2020
- CNTX 2021
- Fundamental
- Price
- PLRX $1.28
- CNTX $0.58
- Analyst Decision
- PLRX Hold
- CNTX Strong Buy
- Analyst Count
- PLRX 10
- CNTX 4
- Target Price
- PLRX $9.79
- CNTX $6.00
- AVG Volume (30 Days)
- PLRX 950.8K
- CNTX 390.0K
- Earning Date
- PLRX 08-06-2025
- CNTX 08-06-2025
- Dividend Yield
- PLRX N/A
- CNTX N/A
- EPS Growth
- PLRX N/A
- CNTX N/A
- EPS
- PLRX N/A
- CNTX N/A
- Revenue
- PLRX N/A
- CNTX N/A
- Revenue This Year
- PLRX N/A
- CNTX N/A
- Revenue Next Year
- PLRX N/A
- CNTX N/A
- P/E Ratio
- PLRX N/A
- CNTX N/A
- Revenue Growth
- PLRX N/A
- CNTX N/A
- 52 Week Low
- PLRX $1.10
- CNTX $0.49
- 52 Week High
- PLRX $16.10
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- PLRX 36.66
- CNTX 44.00
- Support Level
- PLRX $1.56
- CNTX $0.56
- Resistance Level
- PLRX $1.70
- CNTX $0.63
- Average True Range (ATR)
- PLRX 0.12
- CNTX 0.08
- MACD
- PLRX -0.02
- CNTX 0.00
- Stochastic Oscillator
- PLRX 5.68
- CNTX 27.68
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.